
Presenter: Dr. D. Oneschuk
Location: Tertiary Palliative Care Unit, Grey Nuns Hospital
Date: September 9, 2009

Reference: J of Palliative Medicine, Vol 12 (1): 2009

Abstract:
Long-term anticoagulant therapy with Warfarin is part of standard therapy for several disorders commonly present in patients seen in hospice and palliative care programs. Yet warfarin is also the drug most implicated in adverse drug reactions and its risks rise with increasing age and comorbidity. Clinicians caring for patients with multiple comorbidities or a limited life expectancy often are faced with the decision as to whether anticoagulation should be continued. Published guidelines for the use of warfarin in venous thromboembolism and nonvalvular atrial fibrillation are based on studies in which such patients were underrepresented or excluded. Our review of the randomized trials on which these guidelines are based shows that the annual risk of recurrent venous thromboembolism after stopping warfarin is 2%-10%. No similar evidence is available for patients with atrial fibrillation, but the published CHADS(2) index uses multiple factors to estimate stroke risk. The risk of bleeding complications with warfarin is most closely linked to degree of anticoagulation. Nutritional compromise and changes in drug therapy increase this risk and require that any patient remaining on warfarin must undergo frequent monitoring of anticoagulant effect.

Strengths:
Reviews an area of interest and concern, namely duration of warfarin and other anticoagulant use, and when to consider discontinuing anticoagulation at the end of life.

Weaknesses:
The review search was limited to Medline.

Relevance to Palliative Care: Many patients with end stage illness are receiving anticoagulation for a history of venous thromboembolic disease and/or nonvalvular atrial fibrillation. This article discusses numerous articles that address duration of therapy, and appropriateness of continuing or discontinuing anticoagulation at the end of life. A proposed model for decision making regarding warfarin therapy in palliative care and hospice patients is provided.